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Background/aim: Although cutting edge procedures such as cell-free fetal DNA isolation from maternal blood are now available,
invasive prenatal tests are still being used extensively for prenatal diagnosis. The study aims to evaluate the demographic data, indications,
and cytogenetic results of 9297 results of patients who underwent prenatal invasive testing for genetic analysis that were referred for the
last 20 years in a University Medical Genetics Center.
Materials and methods: The records of 8363 amniocenteses, 626 chorionic villus, and 308 cordocenteses samples were retrospectively
evaluated and analyzed regarding referral reasons, indications and their cytogenetic results. The total numbers and the percentages
of each group were recorded; Chi-square and logistic regression analyses were performed to give the statistical likelihood of different
events.
Results: The number of referrals decreased signiﬁcantly after 2009. Risk of having trisomy 21 as well as trisomy 13 and 18 significantly
increased in parallel with advanced maternal age. When the 21–25 age group was compared to the older age groups in terms of having
a trisomy 21 pregnancy, the risk doubled in the 36–40, 5 times higher in 41–45 and 10-fold in 46–50 age groups. No significant linear
correlation between maternal serum screening test results and trisomy 21 was found, however the difference between the pregnancies
whom cut-off value above and below 1/250 in maternal serum screening test were significant.
Conclusion: These data have provided useful information on the frequency of referrals to the reference genetics department, and
the feasibility of genetic services. By reviewing the indications and their corresponding results, we can offer invaluable insights that
will be useful in genetic counseling and also in the development of more effective genetic strategies.
Key words: Prenatal diagnosis, chromosome abnormalities, genetic counseling

1. Introduction
Prenatal screening and diagnostic testing for chromosomal
abnormalities have expanded dramatically over the past
two decades [1]. After reviewing 68,159 live born baby
surveys from 1969 to 1982, 1 in 156 live births were found
to be carrying a major chromosomal abnormality [2]. The
implementation of effective screening tests decreased the
need for invasive diagnostic testing such as amniocentesis
(AC), chorionic-villus sampling (CVS) or cordocentesis;
thus, reducing the risk of procedure-related miscarriages
for a healthy pregnancy. Screening tests, however,
have limitations which include both false positive and
false negative results and currently cannot detect all
chromosomal anomalies.

While more advanced procedures such as cell-free fetal
DNA (cffDNA) testing from maternal blood are available,
invasive prenatal tests are still being used extensively for
prenatal diagnosis in most countries. Amniocentesis and
CVS are considered safe and accurate procedures. The
risk of major complication associated with midtrimester
amniocentesis at 15–16 weeks of gestation is 1 in 1600. The
risk of inducing miscarriage is only approximately 1%–2%
over the baseline risk for any pregnancy at this stage of
gestation [3]. The decision regarding screening to mitigate
the risk having a child with chromosomal abnormality prior
to the child’s birth is very personal and deeply complex.
The presence of a family history of aneuploidy or genetic
disorders, obstetrical and medical history, demographic

* Correspondence: burak.durmaz@ege.edu.tr

This work is licensed under a Creative Commons Attribution 4.0 International License.

1775

DURMAZ et al. / Turk J Med Sci
information, attitudes and religious beliefs, education
levels and economic concerns are all influencing factors
[4]. Investigation of these factors may offer invaluable
insights that will be used in genetic counseling services
prior to prenatal diagnosis, and also in the development
of more effective decision-making strategies. Therefore,
the aim of this study was to evaluate and to discuss the
demographic data, indications and cytogenetic results of
9297 cases that opted for prenatal sampling procedures.

1. Advanced maternal age (AMA) (≥35 years at the
expected time of delivery)
2. Abnormal result of maternal serum screening
tests
3. Abnormal ultrasound (USG) ﬁndings
4. Referral for molecular analysis
5. Chromosome abnormality in previous pregnancy
6. Advanced maternal age with abnormal
ultrasound findings
7. Parental anxiety
8. Abnormal parental karyotype
9. Chromosome abnormality in previous pregnancy
with advanced maternal age
10. Recurrent pregnancy loss
11. Other indications
Cases with both AMA and abnormal USG finding,
or AMA and chromosome abnormality in previous
pregnancy were grouped separately.
Cases were further classified into groups according to
age:
1. 21–25 years
2. 26–30 years
3. 31–35 years
4. 36–40 years
5. 41–45 years
6. 46–54 years

2. Materials and methods
The study was conducted retrospectively using the records
of AC, CVS, and cordocentesis referrals for the last 20
years in a University Medical Genetics Center. A total of
9297 women between 18–54 years old were included in
the study. Invasive prenatal testing was performed for each
case appropriate to its week of gestation (CVS at 10–13
weeks of gestation, AC at 16–22 weeks of gestation, and
cordocentesis at 20–24 weeks of gestation). In all cases,
genetic counseling was provided, outlining the chances
of finding chromosomal abnormality in the fetus and the
risks associated with invasive prenatal testing procedures.
Invasive prenatal testing was performed only after written
informed consent had been obtained.
We grouped the cases according to the standard
indications of prenatal testing (Table 1):

Table 1. Number of chromosomal abnormalities detected in regard to the indications of prenatal diagnosis.

Indications

Number of abnormal
Number of
Number of abnormal
karyotype without
total cases (%) karyotype with inv(9) (%)
inv(9) (%)

Positive
predictive value
(%)

Advanced maternal age

4482 (48.2)

205 (4.5)

160 (3.5)

3.5

Increased risk in MSS tests

2387 (25.7)

107 (4.4)

69 (2.8)

2.8

Abnormal ultrasound findings

1021 (11)

121 (11)

101 (9.8)

9.8

Referral for molecular analysis
Previous pregnancy with chromosome
abnormality
Other indications*

695 (7.5)

14 (2)

5 (0.7)

0.7

249 (2.7)

19 (7.8)

18 (7.2)

7.2

172 (1.8)

6 (3.4)

4 (2.3)

2.3

Advanced maternal age with abnormal
ultrasound findings

106 (1.1)

30 (28)

29 (27.3)

27.3

Maternal anxiety

86 (0.9)

5 (5.8)

4 (4.6)

4.6

Parental abnormal karyotype

41 (0.4)

15 (36.5)

15 (36.5)

36.5

Increased risk in MSS tests with abnormal
ultrasound findings

26 (0.3)

4 (15.3)

4 (15.3)

15.3

Recurrent pregnancy loss

21 (0.2)

3 (14.2)

3 (14.2)

14.2

Previous pregnancy with chromosome
abnormality and advanced maternal age

11 (0.1)

9 (81.8)

9 (81.8)

81.8

Total

9297 (100)

538

421

-

MSS: maternal serum screening, inv: inversion, *stillbirth in previous pregnancy, failure in previous prenatal test
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A positive cytogenetic result was accepted if the
obtained karyotype was other than 46,XX or 46,XY and
these results were grouped as numerical or structural
abnormality. The study was approved by Ege University
Scientific Research Ethics Committee with the approval
number 17-8.1/11.
2.1. Statistical analyses
The total number of events and the percentages of each
group were recorded. Chi-square and logistic regression
analysis were performed in order to give the statistical
likelihood of different events. A p-value of < 0.05 was
considered statistically significant. Positive predictive
values were calculated for each of the prenatal indications
with the cytogenetic results. The Shapiro–Wilk test was
employed to verify the normality of the data. The data
generated from the study were compared and analyzed
using SPSS v: 19.0 software (IBM Corp., Armonk, NY,
USA) with confidence interval set at 95%.
3. Results
Analyses were carried out on 9297 prenatal sample results;
AC (8363 cases), CVS (626 cases), and cordocentesis
(308 cases). The Shapiro–Wilk test revealed normal
distribution of the data (p > 0.05). Our culture success
rate was 98.4%. The rate of chromosomal abnormalities
was found to be 4.5% excluding inversion 9 (inv(9))
polymorphism being trisomy 21 was the most common
cytogenetic abnormality. Mean age for all pregnancies was
33.17±5.9; ranging between 18–54 years, whereas 50.8% of
cases were advanced maternal age (≥35 years of age). The
mean gestational duration of the pregnancies at the time
of testing was 17.4±2.2 weeks. It is interesting to note that
the number of referrals decreased signiﬁcantly after 2009.
By volume, the indications for prenatal diagnosis were
AMA in 4482 cases (48.2%), abnormal maternal screening
tests in 2387 cases (25.7%), abnormal USG ﬁndings in
1021 cases (11.1%), referral for molecular analysis in 695
cases (7.5%), and chromosome abnormality of a previous
pregnancy in 249 cases (2.7%). Further indications
included AMA with abnormal ultrasound finding in 106
cases (1.1%), parental anxiety in 86 cases (0.9%), having
abnormal parental karyotype in 41 cases (0.4%), recurrent
pregnancy loss in 21 cases (0.2%), abnormality in previous
pregnancy with AMA in 11 cases (0.1%), other indications
including stillbirth in previous pregnancy, failure in
previous prenatal test, which accounted for 172 cases,
(1.8%). Table 1 summarizes the detected chromosomal
abnormalities according to the indications of prenatal
diagnosis.
Of the 9297 cases, chromosome anomalies and inv(9)
polymorphism were determined in 538 cases (5.8%).
Numerical abnormalities accounted for 60.1% and
structural abnormalities made up the remaining 39%.
Of the numerical chromosomal abnormalities, trisomy

21 was noted in 167 cases (31%), an abnormality of sex
chromosome in 57 cases (10.6%), trisomy 18 in 42 cases
(7.8%), marker chromosome in 18 cases (3.3%), triploidy
or tetraploidy in 16 cases (3%), trisomy 13 in 13 cases
(2.4%), and mosaic chromosomal abnormalities were
noted in 11 cases (2%). With reference to the structural
anomalies, 64 cases had translocation (11.9%), in which 45
patients had reciprocal, and 19 patients had Robertsonian
translocation, 19 cases of inversion (3.5%), and 10 cases of
deletion (1.9%). Rare structural anomalies were reported
in 4 cases in which 3 cases had derivative chromosome
and 1 case had isochromosome X (0.7%). Additionally,
inv(9) polymorphism was found in 117 cases (21.7%).
Chromosome analysis was recommended from the parents
of patients having structural chromosomal anomalies.
The outcomes of 154 patients, whose records have been
reached, whose parents were alive and who wanted to have
the karyotype analysis were evaluated. Segregation analysis
revealed that, 24 reciprocal translocations, 12 Robertsonian
translocations, 13 inversions, 3 derivative chromosomes, 1
deletion, and 87 inv(9) polymorphisms were segregated
from either parent and noted as familial. On the other hand,
5 reciprocal translocations, 2 Robertsonian translocations,
6 deletions, and 1 isochromosome were de novo. Table 2
summarizes the distribution of numerical and structural
Table 2. Distribution of numerical and structural chromosomal
abnormalities.
Chromosomal
abnormalities

Number (%)

Numerical

324 (60.1)

Trisomy 21
Sex chromosome
abnormality
Trisomy 18

167 (31.0%)

Marker chromosome

18 (3.3%)

Triploidy/tetraploidy

16 (3.0%)

Trisomy 13

13 (2.4%)

Mosaic chromosomal
abnormality

11 (2%)

Structural

214 (39.0%)

Familial/De-novo
n (%)/n (%)

Translocation

64 (11.9%)

36 (23.4%)/7 (4.5%)

Inversion

19 (3.5%)

13 (8.4%)/0 (0%)

Deletion
Rare chromosomal
abnormality*
Inv(9) polymorphism

10 (1.9%)

1 (0.6%)/6 (3.9%)

4 (0.7%)

3 (1.9%)/1 (0.6%)

117 (21%)

87 (56.5%)/0 (0%)

Total

538 (100%)

154 (100%)

57 (10.6%)
42 (7.8%)

*Rare chromosomal abnormality (derivative chromosome
abnormality and isochromosome) (Inv: inversion, n: number).
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chromosomal anomalies.
The indication of “chromosome abnormality in
previous pregnancy with advanced maternal age” was
found to be the most strongly associated with chromosomal
abnormalities (81.8%). A positive predictive value (PPV)
was also detected in other indications such as parental
abnormal karyotype (36.5%), advanced maternal age with
abnormal ultrasound findings (27.3%), increased risk in
MSS tests with abnormal ultrasound findings (15.3%),
recurrent pregnancy loss (14.2%), abnormal ultrasound
findings (9.8%), previous pregnancy with chromosome
abnormality (7.2%), maternal anxiety (4.6%), AMA
(3.5%), increased risk in MSS tests (2.8%), and others
(2.3%). The indication “referral for molecular analysis”
produced a PPV of only 0.7% (Table 1).
Logistic regression analysis revealed a strong
correlation with the risk of having trisomy 21 and AMA
(2.6%, p < 0.001). However, while the risk increased for
AMA pregnancies in terms of trisomy 18 and 13, the
diﬀerence was not statistically signiﬁcant in Chi-square
test (p > 0.05). The risk of having a trisomy 21 pregnancy
was then evaluated across diﬀerent age groups with
logistic regression analysis. When the 21–25 age group
was compared to the older age groups, risk doubled
in the 36–40 age group. This was 5 times and 10 times
higher in the 41–45 and 46–50 age groups, respectively.
Table 3 summarizes the risk of having a child with Down
Syndrome according to the different age groups.
A total of 2387 cases were referred due to increased
risk in maternal serum screening. We were able to access
the detailed data of 1747 cases. In 1497 cases, the risk was
below 1/250 (high risk), and in 250 cases, the risk was
1/250 or higher (low risk). We were able to establish a cutoﬀ value of 1/250 for trisomy 21. However, Chi-square test
was unable to establish any signiﬁcant correlation between
maternal serum screening test results higher than 1/250
Table 3. Risk of having a child with Down Syndrome (DS)
compared to age range of 21–25.

26–30

DS risk
(X)
1

31–35
36–40

Age

B

S.E

OR

%95 C.I.

p

0.143 0.389 1.154 0.538–2.475

0.713

1

0.120 0.372 1.127 0.543–2.337

0.748

2

0.806 0.339 2.238 1.151–4.351

0.018*

41–45

5

1.669 0.363 5.305 2.603–10.814 <0.001*

46–54

10

2.285 684

9.83 2.573–37.555 0.001*

The risk is given as (X) times. The dependent variable is the
presence of Down Syndrome and the independent variable is the
maternal age, grouped in accordance with our study population.
(B:beta, S.E: standard error, OR: odds ratio, C.I.: confidence
interval, *:p < 0.05).
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and trisomy 21 occurrence (p > 0.05). All the pregnancies
that were found to have trisomy 21 also had an increased
risk in maternal serum screening which is below 1/250
cut-off value.
4. Discussion
Genetic counseling is an essential step prior to prenatal
testing and plays a very important role in meeting
the expectations of families about prenatal screening
tests. Understanding the risks and the likelihood ratio
of detecting chromosomal abnormalities when these
procedures were applied, have become very important
aspects of the pretest genetic counseling [5]. In this study,
chromosomal abnormalities has been reported in 4.5% of
all cases with the exception of inv(9) polymorphism which
is higher than the previous reports [4,6–8]. AMA is a wellknown risk factor for chromosomal abnormality [6–11].
The detection rate of abnormal karyotype in women over
≥35 years old was higher than that previously reported by
Xiao et al. (2.79%) [8]. However, it is similar to the study
reported by Balkan et al. (4.9%) [12].
In our study, the main indication for prenatal testing
was AMA and the second indication was the presence
of abnormal MSS tests. In recent years, particularly in
developed countries, the mean age of pregnant women
has increased [13]. In previous studies, while the most
common indications for prenatal testing were AMA
[14,15] and MSS [9], with the increased development of
MSS procedures, chromosomal abnormality detection
rates have increased to higher rates. This caused MSS
tests to become a more frequent indication for an invasive
testing [16]. In a recent retrospective study, it was
shown that there was a significant change in the trend of
indications for invasive prenatal diagnosis from advanced
maternal age in 2009 to positive screening tests by 2014
[17]. In a study from Turkey, highest chromosomal
anomaly detection rate was observed in pregnant women
with increased risk in MSS (3.2%) [18]. Although the use
of noninvasive maternal next generation screening tests
is gradually increasing, their sensitivity and specificity
should be questioned. Therefore, the meaning of the rates
determined in traditional screening tests should also be
well explained in genetic counseling sessions. In our study,
there was no increase in the rate of chromosomal anomaly
detection rate in parallel with the rate determined in
MSS. However, trisomy 21 detection rate was significantly
higher in women having a MSS test above 1/250 cut-off
value [18]. An important aspect of prenatal care has always
been the consideration of trisomy 21. In our study, the
risk of having a trisomy 21 pregnancy was also evaluated
across diﬀerent age groups. When the 21–25 age group
was compared to the older age groups, risk doubled in
the 36–40 age group. This was found to be 5 and 10 times
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increased in 41–45 and 46–50 age groups, respectively.
However, we have not found any significant association
between AMA and trisomy 13 or trisomy 18.
The indication of “Chromosome abnormality in
previous pregnancy with advanced maternal age” was
found to be the indication, most strongly associated with
any chromosomal abnormality (81.8%). It was considered
to be a high indicator of an abnormal karyotype;
therefore, the cytogenetic results should be thoroughly
reviewed for any subtle chromosomal abnormality. “Fetal
anomalies in prenatal ultrasonography” was the most
common indication in some other studies associated with
chromosomal anomalies which ranged between 5.3%–
20.3% [14–15,19–21]. Our PPV value for abnormal USG
findings was 9.8% which was similar to previous results.
Moreover, accompanying indications such as “advanced
maternal age” or “abnormal MSS tests” in conjunction with
abnormal USG findings increased the PPV value. Advanced
maternal age with abnormal USG findings produced a
rate of 27.3%, whilst abnormal MSS tests together with
abnormal ultrasound findings had a rate of 15.3%. In a
recent study by Sun et al. demonstrated that ultrasound
soft markers were the most common prenatal diagnostic
indication among 3387 patients, but the detection rate of
abnormal karyotypes was only 2.02%. Additionally, it was
46.97% in the genome-wide NIPT-positive group which
they concluded that NIPT should not be recommended
as the first-tier screening for chromosomal aberration for
pregnancies with ultrasound soft markers or pathological
ultrasound findings [22].
There is an increase in the demand for prenatal tests
due to lower costs and availability particularly after 2003.
Amniocentesis is the most preferred prenatal procedure
as, a 5-year retrospective study showed that, 86% of
amniocentesis were safe and free from any complications
[23]. Although the range and quality of prenatal tests

have increased over the years, the number of requests for
these tests in our department has declined since 2009.
One possible explanation could be the decentralization of
specialized services. The fact that these tests can now be
carried out in more provincial hospitals may explain the
decline since 2009. A cheaper, faster, and less intrusive
option of USG imaging and combined screening tests
together with noninvasive next generation prenatal
screening may have also contributed to this decline.
Moreover, our culture success rate was 98.4%, which
was around in the level of upper range in the studies
reported from our country. In one of those studies, a
cytogenetic result could be obtained in 98.8% of the 6124
cases evaluated by using AC [24]. In another study the
culture success rate was 99% [25]. However, these studies
reported only amniocentesis data. To gain a broader
perspective, our study included all forms of prenatal
sampling procedures.
5. Conclusion
As technology evolves, the opportunity for early diagnosis
of genetic diseases has become a very useful addition to
the healthcare system. We think that, by reviewing these
indications and their corresponding results, it provides
a helpful insight for genetic counseling prior prenatal
diagnosis and also adds useful background to the strategic
development of effective and long-term genetic services.
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